Literature DB >> 8988735

18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.

F G Barker1, S M Chang, P E Valk, T R Pounds, M D Prados.   

Abstract

BACKGROUND: After intensive initial radiation therapy for malignant glioma, magnetic resonance imaging (MRI) and computerized tomography (CT) cannot distinguish tumor progression from radiation injury.
METHODS: The authors studied the prognostic value of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in 55 patients with malignant glioma for whom MRI obtained after initial surgery and radiation therapy demonstrated enlarging, enhancing lesions consistent with either tumor progression or radiation necrosis. Forty patients (73%) had an initial diagnosis of Grade 4 malignant glioma and 15 (27%) had Grade 3 malignant glioma. The FDG-PET scans were graded visually on a four-level scale at the time of acquisition.
RESULTS: In univariate analysis, the FDG-PET score was a significant predictor of survival time after FDG-PET scanning (P = 0.005). Median survival was 10 months for patients with FDG-PET scores of 2 or 3 (glucose uptake > or = adjacent cortex) and 20 months for those with scores of 0 or 1 (glucose uptake < adjacent cortex). In multivariate proportional hazards analysis, the FDG-PET score was a significant predictor of survival (P = 0.019) in a model that included patient age, recurrence number, and FDG-PET score. There was no significant difference in the FDG-PET score hazard ratio for patients with Grade 3 or 4 tumors at initial diagnosis, first or later suspected recurrence, initial photon irradiation given with standard fractions or hyperfractionation, or stereotactic irradiation prior to FDG-PET scanning.
CONCLUSIONS: This analysis demonstrates that FDG-PET scanning has prognostic value in a cohort limited to patients with suspected recurrent high grade glioma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8988735

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  Prediction of pathology and survival by FDG PET in gliomas.

Authors:  M V Padma; S Said; M Jacobs; D R Hwang; K Dunigan; M Satter; B Christian; J Ruppert; T Bernstein; G Kraus; J C Mantil
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

Review 3.  Recent advances in the treatment of oligodendrogliomas.

Authors:  Mark Agulnik; Warren P Mason
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

Review 4.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

5.  Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Authors:  Ken Herrmann; Johannes Czernin; Timothy Cloughesy; Albert Lai; Kelsey L Pomykala; Matthias R Benz; Andreas K Buck; Michael E Phelps; Wei Chen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

6.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Authors:  Cécile Colavolpe; Olivier Chinot; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Bequet-Boucard; Emeline Tabouret; Olivier Mundler; Dominique Figarella-Branger; Eric Guedj
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

7.  Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium.

Authors:  Katherine A Zukotynski; Frederic H Fahey; Sridhar Vajapeyam; Sarah S Ng; Mehmet Kocak; Sridharan Gururangan; Larry E Kun; Tina Y Poussaint
Journal:  J Nucl Med       Date:  2013-06-25       Impact factor: 10.057

8.  [Molecular imaging in neurological diseases].

Authors:  M Reimold; C la Fougère
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 9.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

10.  Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.

Authors:  A G Vlassenko; B Thiessen; B J Beattie; M G Malkin; R G Blasberg
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.